Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Operating Leases: 2019-2025

Historic Operating Leases for Keros Therapeutics (KROS) over the last 5 years, with Sep 2025 value amounting to $15.1 million.

  • Keros Therapeutics' Operating Leases fell 21.65% to $15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year decrease of 21.65%. This contributed to the annual value of $16.9 million for FY2024, which is 25.63% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Operating Leases is $15.1 million, which was down 3.90% from $15.7 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Operating Leases peaked at $19.3 million during Q3 2024, and registered a low of $231,000 during Q4 2021.
  • Its 3-year average for Operating Leases is $15.0 million, with a median of $14.3 million in 2023.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 65.03% in 2021, then skyrocketed by 5,484.42% in 2022.
  • Over the past 5 years, Keros Therapeutics' Operating Leases (Quarterly) stood at $231,000 in 2021, then spiked by 5,484.42% to $12.9 million in 2022, then increased by 4.18% to $13.4 million in 2023, then climbed by 25.63% to $16.9 million in 2024, then dropped by 21.65% to $15.1 million in 2025.
  • Its Operating Leases stands at $15.1 million for Q3 2025, versus $15.7 million for Q2 2025 and $16.3 million for Q1 2025.